Sign in Subscribe
Cancer research

Comprehensive Analysis of Cancer Diagnosis Pathway for Non-Specific Symptoms

Strategic Insights

— 1 min read

Researchers at the University of Oxford's Nuffield Department of Primary Care Health Sciences have conducted a major UK study to analyze a cancer diagnosis pathway for patients presenting with non-specific symptoms (NSS), such as unexplained weight loss or fatigue. The study, published in the Lancet Primary Care, tracked over 4,800 patients referred to the SCAN Pathway between 2017 and 2023, revealing a 29.7% positive predictive value for cancer when abnormal CA125 levels were present. The findings support the value of non-specific symptom pathways in identifying hard-to-diagnose cancers, but also highlight the considerable number of incidental findings that can place additional pressure on healthcare systems.

Key Takeaways:

  • Over the six years tracked, 8.8% of patients were diagnosed with cancer, most commonly lung, pancreatic, breast, non-Hodgkin lymphoma, and colorectal, with a total of 428 cancer diagnoses out of 4,800 patients (9.0%).
  • An additional 10.9% received serious non-cancer diagnoses, highlighting the complexity and resource demands of these pathways.
  • 19.3% had clinically significant incidental findings, underscoring the attention needed for non-specific symptom pathways.
  • Certain combinations of symptoms and test abnormalities significantly increased the likelihood of a cancer diagnosis, such as abnormal CA125 levels (29.7% positive predictive value).
  • The SCAN Pathway, developed in partnership with NHS England, Cancer Research UK, and Macmillan Cancer Support, has been adopted as standard care across the region and is part of the NHS's wider rollout of Rapid Diagnostic Centres nationwide.
  • Early diagnosis of cancers could save thousands of lives each year and significantly reduce treatment costs for the NHS, as late-stage cancer care is considerably more expensive.

Statistics:

  • 428 patients were diagnosed with cancer across the six-year period, representing 8.8% of the cohort (4,800 patients).
  • 530 patients received serious non-cancer diagnoses, accounting for 10.9% of the cohort.
  • 924 patients had clinically significant incidental findings, or 19.3% of the cohort.
  • Over 29.7% of patients with abnormal CA125 levels were diagnosed with cancer.

Sources:

  • "UK study finds that non-specific symptoms pathways can detect hard-to-diagnose cancers"

+ Lancet Primary Care [but date not specified]

  • University of Oxford press release [no date specified]

Read more